Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19: A SECURe Prospective Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19 : A SECURe Prospective Cohort Study. / Arndal, Elisabeth; Lebech, Anne Mette; Podlekarava, Daria; Mortensen, Jann; Christensen, Jan; Rönsholt, Frederikke F.; Lund, Thomas Kromann; Katzenstein, Terese L.; von Buchwald, Christian.

I: Journal of Clinical Medicine, Bind 11, Nr. 20, 6025, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Arndal, E, Lebech, AM, Podlekarava, D, Mortensen, J, Christensen, J, Rönsholt, FF, Lund, TK, Katzenstein, TL & von Buchwald, C 2022, 'Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19: A SECURe Prospective Cohort Study', Journal of Clinical Medicine, bind 11, nr. 20, 6025. https://doi.org/10.3390/jcm11206025

APA

Arndal, E., Lebech, A. M., Podlekarava, D., Mortensen, J., Christensen, J., Rönsholt, F. F., Lund, T. K., Katzenstein, T. L., & von Buchwald, C. (2022). Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19: A SECURe Prospective Cohort Study. Journal of Clinical Medicine, 11(20), [6025]. https://doi.org/10.3390/jcm11206025

Vancouver

Arndal E, Lebech AM, Podlekarava D, Mortensen J, Christensen J, Rönsholt FF o.a. Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19: A SECURe Prospective Cohort Study. Journal of Clinical Medicine. 2022;11(20). 6025. https://doi.org/10.3390/jcm11206025

Author

Arndal, Elisabeth ; Lebech, Anne Mette ; Podlekarava, Daria ; Mortensen, Jann ; Christensen, Jan ; Rönsholt, Frederikke F. ; Lund, Thomas Kromann ; Katzenstein, Terese L. ; von Buchwald, Christian. / Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19 : A SECURe Prospective Cohort Study. I: Journal of Clinical Medicine. 2022 ; Bind 11, Nr. 20.

Bibtex

@article{3fd3f4ba49e249d8bce837594efe3e35,
title = "Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19: A SECURe Prospective Cohort Study",
abstract = "Background: Long-term follow-up studies of COVID-19 olfactory and gustatory disorders (OGDs) are scarce. OGD, parosmia, and dysgeusia affect health-related quality of life (HRQoL) and the ability to detect potential hazards. Methods: In this study, 29 patients reporting OGD 1 month after severe-to-critical COVID-19 were tested at 3–6 months and retested at 12 months in case of hyposmia/anosmia. We used Sniffin Sticks Threshold, Discrimination, and Identification (TDI) test, Sniffin Sticks Identification Test (SIT16), Brief Smell Identification Test (BSIT), taste strips, and HRQoL. The patients were part of the prospective SECURe cohort. Results: Overall, 28% OD (TDI), 12% GD, 24% parosmia, and 24% dysgeusia (questionnaire) at 3–6 months (n = 29) and 28% OD (TDI), 38% parosmia, and 25% dysgeusia (questionnaire) at 12 months (n = 8) were observed. OGD decreased HRQoL: For 13%, it had a negative effect on daily life and, for 17%, it affected nutrition, 17% reported decreased mood, and 87–90% felt unable to navigate everyday life using their sense of smell and taste. A comparison of SIT16 and BSIT to TDI found sensitivity/specificity values of 75%/100% and 88%/86%. Conclusions: This is the first study to examine TDI, SIT16, BSIT, taste strips, and HRQoL up to 1 year after severe-to-critical COVID-19. The patients suffering from prolonged OGD, parosmia, and dysgeusia experienced severely decreasing HRQoL. We recommend including ear–nose–throat specialists in multidisciplinary post-COVID clinics.",
keywords = "BSIT, COVID-19, dysgeusia, gustation, HRQoL, olfaction, parosmia, SIT, TDI",
author = "Elisabeth Arndal and Lebech, {Anne Mette} and Daria Podlekarava and Jann Mortensen and Jan Christensen and R{\"o}nsholt, {Frederikke F.} and Lund, {Thomas Kromann} and Katzenstein, {Terese L.} and {von Buchwald}, Christian",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
doi = "10.3390/jcm11206025",
language = "English",
volume = "11",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "20",

}

RIS

TY - JOUR

T1 - Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3–6 and 12 Months after Severe-to-Critical COVID-19

T2 - A SECURe Prospective Cohort Study

AU - Arndal, Elisabeth

AU - Lebech, Anne Mette

AU - Podlekarava, Daria

AU - Mortensen, Jann

AU - Christensen, Jan

AU - Rönsholt, Frederikke F.

AU - Lund, Thomas Kromann

AU - Katzenstein, Terese L.

AU - von Buchwald, Christian

N1 - Publisher Copyright: © 2022 by the authors.

PY - 2022

Y1 - 2022

N2 - Background: Long-term follow-up studies of COVID-19 olfactory and gustatory disorders (OGDs) are scarce. OGD, parosmia, and dysgeusia affect health-related quality of life (HRQoL) and the ability to detect potential hazards. Methods: In this study, 29 patients reporting OGD 1 month after severe-to-critical COVID-19 were tested at 3–6 months and retested at 12 months in case of hyposmia/anosmia. We used Sniffin Sticks Threshold, Discrimination, and Identification (TDI) test, Sniffin Sticks Identification Test (SIT16), Brief Smell Identification Test (BSIT), taste strips, and HRQoL. The patients were part of the prospective SECURe cohort. Results: Overall, 28% OD (TDI), 12% GD, 24% parosmia, and 24% dysgeusia (questionnaire) at 3–6 months (n = 29) and 28% OD (TDI), 38% parosmia, and 25% dysgeusia (questionnaire) at 12 months (n = 8) were observed. OGD decreased HRQoL: For 13%, it had a negative effect on daily life and, for 17%, it affected nutrition, 17% reported decreased mood, and 87–90% felt unable to navigate everyday life using their sense of smell and taste. A comparison of SIT16 and BSIT to TDI found sensitivity/specificity values of 75%/100% and 88%/86%. Conclusions: This is the first study to examine TDI, SIT16, BSIT, taste strips, and HRQoL up to 1 year after severe-to-critical COVID-19. The patients suffering from prolonged OGD, parosmia, and dysgeusia experienced severely decreasing HRQoL. We recommend including ear–nose–throat specialists in multidisciplinary post-COVID clinics.

AB - Background: Long-term follow-up studies of COVID-19 olfactory and gustatory disorders (OGDs) are scarce. OGD, parosmia, and dysgeusia affect health-related quality of life (HRQoL) and the ability to detect potential hazards. Methods: In this study, 29 patients reporting OGD 1 month after severe-to-critical COVID-19 were tested at 3–6 months and retested at 12 months in case of hyposmia/anosmia. We used Sniffin Sticks Threshold, Discrimination, and Identification (TDI) test, Sniffin Sticks Identification Test (SIT16), Brief Smell Identification Test (BSIT), taste strips, and HRQoL. The patients were part of the prospective SECURe cohort. Results: Overall, 28% OD (TDI), 12% GD, 24% parosmia, and 24% dysgeusia (questionnaire) at 3–6 months (n = 29) and 28% OD (TDI), 38% parosmia, and 25% dysgeusia (questionnaire) at 12 months (n = 8) were observed. OGD decreased HRQoL: For 13%, it had a negative effect on daily life and, for 17%, it affected nutrition, 17% reported decreased mood, and 87–90% felt unable to navigate everyday life using their sense of smell and taste. A comparison of SIT16 and BSIT to TDI found sensitivity/specificity values of 75%/100% and 88%/86%. Conclusions: This is the first study to examine TDI, SIT16, BSIT, taste strips, and HRQoL up to 1 year after severe-to-critical COVID-19. The patients suffering from prolonged OGD, parosmia, and dysgeusia experienced severely decreasing HRQoL. We recommend including ear–nose–throat specialists in multidisciplinary post-COVID clinics.

KW - BSIT

KW - COVID-19

KW - dysgeusia

KW - gustation

KW - HRQoL

KW - olfaction

KW - parosmia

KW - SIT

KW - TDI

UR - http://www.scopus.com/inward/record.url?scp=85140788795&partnerID=8YFLogxK

U2 - 10.3390/jcm11206025

DO - 10.3390/jcm11206025

M3 - Journal article

C2 - 36294346

AN - SCOPUS:85140788795

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 20

M1 - 6025

ER -

ID: 328431793